Healthcare and sustainability-focused VC firm Flagship Ventures has appointed Stephane Bancel as a senior partner.
In his new role, Bancel will provide strategic counsel and support to portfolio companies, the firm said.
Bancel also serves as president and CEO of Moderna Therapeutics, a Flagship VentureLabs – founded company.
He is also executive chairman of the board for Nasdaq-listed BG Medicine, a Flagship portfolio company focused on biomarker-based diagnostics.
“Stephane brings with him a wealth of management experience and expertise in the development and commercialisation of medical diagnostic tools and technologies as well as expertise in the pharmaceuticals industry,” said Noubar Afeyan, managing partner and CEO of Flagship Ventures.
“Having worked together with Stephane for over three years now at BG Medicine and Moderna, I look forward to seeing his commercial mindset and strategic insights applied more broadly to Flagship’s investment strategy as well as to the growth and success of our portfolio companies.”
Bancel previously served as CEO of Euronext-listed bioMerieux and was managing director of Eli Lilly in Belgium
Founded in 2000, and based in Cambridge, Massachusetts, Flagship manages over $900m in capital. Notable portfolio companies include AeroDesigns, Affinnova, Agios, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna Therapeutics, which it led a $40m round for in December 2012.
Copyright © 2012 AltAssets